AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction

Recruiting now

Conditions studied: Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy

In brief

This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

Key facts

Study ID

NCT06512259

Run by

AlloSource

People needed

200

Starts

2023-10-19

Expected to finish

2026-12-31

Last updated by the study team

2025-11-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet the following inclusion criteria to participate in this study:
• Diagnosed by a physician and required a single or double mastectomy followed by Pre-Pectoral Breast Reconstruction surgery with the use of AlloMend® Acellular Dermal Matrix allograft;
• Surgical intervention using AlloMend® Acellular Dermal Matrix allograft was used;
• Has completed or will complete the anticipated clinically indicated follow-up visits at 2 weeks, 6 weeks, 3 months, and 6 months post-surgical intervention.

You may not qualify if…

• Patients must not meet any of the following criteria to be considered for this clinical trial:
• Did not utilize AlloMend® Acellular Dermal Matrix allograft during pre-pectoral breast reconstruction
• Did not have post-operative evaluations at the clinical site.

Where it is running

• Alan H. Chen Surgical Associates, PC — Joliet, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.